



## LPPFUSION

### 2021-22 Report

## *Dear investors,*

In the past year, LPPFusion has achieved a new world record for the purity of a fusion-producing plasma. The impurity levels in the plasma have decreased three-fold from that achieved in the previous 2019 experiments with beryllium electrodes and are at least ten times less than those reported for any other fusion device. Reducing impurity levels has long been extremely important in fusion research. First of all, impurity elements can greatly increase radiation that cools the plasma, preventing the achievement of the high temperatures needed for fusion.

Second, the erosion processes that produce the impurities by vaporizing device components reduce their lifetime. Finally, the same erosion processes, if fast enough, can cause experimental results to deteriorate even in the course of a few months of experiments. LPPFusion's reduction of impurity levels below any achieved elsewhere is thus a major step forward for fusion research.

LPPFusion's new world record joins two other records we have earlier achieved. In 2016 we achieved, and published, the world record for confined ion energy of over 200 keV (the equivalent of more than 2 billion degrees, 200 times hotter than the center of the sun). That same year our FF-1 device achieved the highest ratio of fusion energy output to device energy input of any private fusion research effort. With only \$9 million spent so far on our project, **LPPFusion's three records make us a world leader in the development of fusion energy.**

While our new ultrafast switches to feed current to our device have taken much longer than expected to perfect, we have made good progress and are confident that we will soon have them working as planned, leading to major increases in fusion yield. We also expect to soon begin experiments with our target fuel, hydrogen-boron or pB11.

### **We need your help!**

We need lots of help in getting the word out about our advances to the mass media and on social media. We want investors to contact local media outlets, present our work at relevant energy technology meetings, organize local meetings and put news of our on websites. We also need

technology, meetings, organize local meetings and put them on record. We also need additional help from those with specialized technical expertise, such as electrical and mechanical engineering, and computer simulations.

*Sincerely,*

*Rudolph Fritsch*

Secretary Treasurer

*Ivana Karamitsos*

CIO

*Eric J. Lerner*

President and Chief Scientist

## Our Mission

To achieve the future we want for ourselves and our children, we must replace fossil fuels with a cheap, clean, safe, and unlimited energy source. Our small, decentralized 5 MW generators will use hydrogen and boron fuel, both of which are essentially unlimited in nature, to allow a direct conversion of energy to electricity without expensive turbines or radioactive waste. We believe costs will be 10x cheaper than existing energy sources, meaning our Focus Fusion technology can change the world.

[See our full profile](#)



## How did we do this year?

*Report Card*

**B+**



## The Good

Achieved a new world record for the purity of a fusion-producing plasma.

Made progress in getting our new ultra-fast switches to work.

Raised nearly \$1 million in new capital



## The Bad

Switches took much longer than expected to perfect

Pandemic shut-downs cut off our access to major libraries until recently

Media coverage of our work continues to be limited

## 2021-22 At a Glance

Fiscal Year Ends September 30



**\$0**

Revenue



**-\$702,312**

Net Loss



**\$11,989 [95%]**

Short Term Debt



**\$1,423,755**

Raised in 2021-22



**\$40,004**

Cash on Hand  
As of 06/10/22

INCOME

BALANCE

NARRATIVE

### Management's Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes and other financial information included elsewhere in this offering. Some of the information contained in this discussion and analysis, including information regarding the strategy and plans for our business, includes forward-looking statements that involve risks and uncertainties. You should review the "Risk Factors" section for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.

#### Overview

We're on a near-term path to achieving nuclear fusion energy at a low enough cost to replace all fossil-fuel based energy sources and end fossil fuel use. We will harness the energy source that powers the sun to create clean, safe energy. If we

secure the funding to complete our project, we believe this will be the most fundamental change in technology in decades. It will flip the power from fossil to fusion.

To achieve the future we want for ourselves and our children, we must replace fossil fuels with a cheap, clean, safe, and unlimited energy source. Our small, decentralized 5 MW generators will use hydrogen and boron fuel, both of which are essentially unlimited in nature, to allow a direct conversion of energy to electricity without expensive turbines or radioactive waste. We believe costs will be 10x cheaper than existing energy sources, meaning our Focus Fusion technology can change the world.

Given the Company's limited operating history, the Company cannot reliably estimate how much revenue it will receive in the future, if any.

### **Milestones**

LAWRENCEVILLE PLASMA PHYSICS, INC. was incorporated in the State of New Jersey in May 2003.

Since then, we have:

- Achieved the highest confined temperature of any fusion experimental device, over 2 billion degrees, sufficient for hydrogen-boron fusion.
- Highest fusion energy output per unit energy input of any private fusion experiment, more than 300 times the closest competitor.
- World record for plasma purity in a fusion device
- Patents issued in the U.S., China, Australia, Canada, and the European Union, with patent pending in India.
- Collaborating with international network of 40 labs organized by the International Center for Magnetized Plasmas.
- Raised over \$9 million from over 1,000 investors.
- Research published in leading peer-reviewed journals documenting the LPP Fusion device as the most advanced, privately funded fusion experiment in the world.
- Easiest path to fusion by using natural instabilities of plasmas, not fighting them. We imitate nature.

### **Historical Results of Operations**

- *Revenues & Gross Margin.* For the period ended September 30, 2021, the Company had revenues of \$128,501 compared to the year ended September 30, 2020, when the Company had revenues of \$74,384. Our gross margin was 100.0% in fiscal year 2021, compared to 100.0% in 2020.
- *Assets.* As of September 30, 2021, the Company had total assets of \$651,669, including \$254,143 in cash. As of September 30, 2020, the Company had \$624,019 in total assets, including \$246,004 in cash.
- *Net Income.* The Company has had net income of \$699,880 and net losses of \$737,056 for the fiscal years ended September 30, 2021 and September 30, 2020, respectively.
- *Liabilities.* The Company's liabilities totaled \$11,989 for the fiscal year ended

September 30, 2021 and \$247,480 for the fiscal year ended September 30, 2020.

## **Liquidity & Capital Resources**

To-date, the company has been financed with \$9,296,357 in equity.

After the conclusion of this Offering, should we hit our minimum funding target, our projected runway is 4 months before we need to raise further capital.

We plan to use the proceeds as set forth in this Form C under "Use of Funds". We don't have any other sources of capital in the immediate future.

We will likely require additional financing in excess of the proceeds from the Offering in order to perform operations over the lifetime of the Company. We plan to raise capital in 6 months. Except as otherwise described in this Form C, we do not have additional sources of capital other than the proceeds from the offering. Because of the complexities and uncertainties in establishing a new business strategy, it is not possible to adequately project whether the proceeds of this offering will be sufficient to enable us to implement our strategy. This complexity and uncertainty will be increased if less than the maximum amount of securities offered in this offering is sold. The Company intends to raise additional capital in the future from investors. Although capital may be available for early-stage companies, there is no guarantee that the Company will receive any investments from investors.

## **Runway & Short/Mid Term Expenses**

LAWRENCEVILLE PLASMA PHYSICS, INC. cash in hand is \$40,004, as of June 2022. Over the last three months, revenues have averaged \$225/month, cost of goods sold has averaged \$0/month, and operational expenses have averaged \$65,400/month, for an average burn rate of \$65,175 per month. Our intent is to be profitable in 50 months.

Since the date our financials cover, we have achieved a world record in plasma purity. We also identified several problems with our switch designs and are now finalizing new designs which we expect to test in July.

Over the next 3 to 6 months, we expect revenue to continue to be small and expenses to continue at the same level, around \$65,000/month.

We are not profitable as we are still in the research phase of developing our Focus Fusion generator technology. We expect to be profitable once we complete both the research and development phase and start to sell licenses. We currently expect this to happen around 2026.

We expect that investments in our shares will fully cover our expenses and allow us to build up a reserve.

However, to reach profitability in the next 4-5 years, we will need much larger funds, in the region of \$100 million. We expect to be able to raise these funds once we have completed the present research phase and have demonstrated net energy production in the lab. We expect that these funds will come from a combination of government grants and large investments, which we think we have a good chance of obtaining once we demonstrate we are the first to attain net energy for a fusion energy device.



[LPPFusion\\_Final\\_Audit\\_Report.pdf](#)

# We ♥ Our 1409 Investors

## Thank You For Believing In Us


Peter Sabourin	Roger Stout	Dauren Sarsenov	Venoodhar Reddy	Michael Dreiling	Luis Gabriel Cabrera Mora	Andrew Lyjak
Thomas Rorvik Skjolberg	Paul Isaak Leitner	Rem Darbinyan	Steve Brady	Andrew C Laufer	Tæd Wynnell	Richard Roederer
Arie Baratz	Guilherme Guidolin De Ca...	Rafael Lobe	Mark Dargan	Matthieu Speeckaert	Patricia Moschella Brady	Mark Vozzo
Roger Bates	Richard Fallenbaum	Charles L Wilcox	Robert Sullivan	Justin L Cherubim	Jim Burtoft	Ian Taylor
Edgar Benjamin Cabrera	Sebastian Kaliszewski	Sean Hennessey	Charles McClain	E. Timlin	Timothy R Klein	Peter Catalano
Amol Mozarkar	Stanley Forward	Jonas V. Butkus	Hector Romay	Joe Warwick	Mark Klapheke	Msuega Tese
Vernon M Risinger	Richard Lee	Marvin Phipps	Colin Phipps	Guidano Napoli	Alan Jacobson	Henry Henderson
Arnaud STEVINS	Kevin Kwok	Dewayne Higgs	Titus Oparaocha	Carsten Czerny	Purba Ganguly	Franklin Scruggs
Deon Mouton	Bernard Ogon	Michael Houston	Jenet Burgos	Craig J. Vom Lehn	Andrea Villot	Ignas Galvelis
Yoav Getzler	George Cigale	Rodney Mills	Jeff Schulman	Jonas V. Butkus	Georgios Papadimitriou	Peter Sabourin
Jamie Rogers	Clay Fulk	Jesse Adamson	Adam Cole	Sajad Zalzal	Melvin Kasanrokijat	David Gillie
Nathan Hineline	Allen Pestaluky	Dan Luhman	Rafael Lobe	Naresh Ravi	Clinton Noel Foster, SR	Peter Catalano
Roger Stout	Janelle Cooper	Thomas Rorvik Skjolberg	Roger Bates	Charles L. Wilcox	Kirit K Patel	Pedro Leonardo
Keith Davis	Ronald Christian Jr	Stuart Watkins	Mohammad Rezaul Karim	Chin Sin Yeo	Rajkumar NATARAJAN	Andrew Lyjak
Jeremy C Hansen	Inamulhaque Saboor	Giuseppe Fedele	Antonin Kral	Dewayne Higgs	Jamail Bogany	Randall Santo Spires
Michael Rush Waghorne	Lee Choon Nam	Christopher Spadaccini	Mohammad Rezaul Karim	Johan C Nowack	Daniel Gonzale	Travis Haberjak
Adric Samuel	Nathan Hineline	Christopher Onwuka	Tom Micle	Thomas Laffesh	Lewis Palmer III	Alan Pence
Dalils Jelani Clendeninn	Tamarat Alumu	Herman Venter	Roger Bates	Angelique Sullivan	Yohance Williamson	Mohammed AlMajid
Christoph Schiller	Gilberto Rodriguez	Billy Engler	Billy Engler	Kheng Hon Franky Tan	Victor Perez-Cotapos	Victor Perez-Cotapos
Hatem Rowaihy	William Brown	Rafael Lobe	Kelly McDonald	Henry Henderson	Jonathon Rice	Jonathon Rice
Alex Kahn	Donald Kulp	Adam MacDonald	Le Andre Watts	Greg Aldrich	Dewayne Higgs	Dewayne Higgs
Kevin Earl Lee	Gregory J McSpadden	Damon Anderson	Warren Sander	Andre Harrell	Henry B Harris	Henry B Harris
Gavin Rens	Mark Wright	Bryce W Ballew	Kevin Moore	Warren Parad	Phillip Rosen	Inamulhaque Saboor
Takeo Aso	Roy G Compton	Shahid Insaf	Maurice Hayles	Ari Cohen	Cooper Walton	Charles Johnson
Andrew John Poole	Richard Fallenbaum	Pheiraoh Griszzyly Ramsee...	Brandon Moquist	Sadhasivarej Nadarajan M...	David Scott Dautremont	Lester Erwin
Brendan York	Bolanle Ige	Melvin Sanicas	Dominick Savillo	Andres Castano	David J Geaney	Lance Recker
Debra Farber	Jalem Correia	Thomas Rorvik Skjolberg	Mohd Shaharuddin Bin M...	Nathan Hineline	Daniel Herrera	Christie Okoroafor
Mirko Turrina	Andre Harrell	Rafael Lobe	Oskar A. Hjartarson	Pandora Jacobitz	Chamal Panditharatne	Eelco Broekmeulen
John Ehn	Richard Houghton	Seth Carlson	Arnaud Vigue	Jamie Goodfellow	Jason Green	Chris Kuether
Gerard DUBOSSON	Kevin Brewster	Roger Swearingen	Neal Howlett	Andy Spreadbury	Khaled Naim	Alan Carden
Shaun Mann Tuyuri	Chuck Daniels	Jeff Fuja	David Chang	Robert Leshner	Steve Adams	Richard Poole
Marcos Pereira REIS	Johannes FrieB	Gary Davis	Eran Zaidman	Jeff Allen Wang	Justin Elliott	Adrian Gonzales
Joe Broughton	Samuel Q DUQUE	Soufou Saechao	Scott Li	Nick Hoath	Peter Torre	James Harbal
Johan Strombom	Ben Smith	Raju Mathew	Eric Lenington	Susan Miller Brake	Steven Kaplan	Donna Johnson
Keith Edwards	Joseph Ibershoff	Georges Zakar	Sonia Siaw	Sean Marsland	Carolyn Smith	Daniel Dunn
Basak Akyollu	Andrew Smith	Kelley Trezise	Felipe Andres Piedra	Alvaro Angel Rodriguez ...	Kate Mullen	Bryant Lee
Bekker Jens	Paolo Manca	Aman Doad	Dr. Paul Nathan	Donald L. MORTON	Pamela Jones	Muthuswamy Sankarapan...
Peerapong Kamolrungvar...	Jessica Vitale	Steven Gorman	Roger Swearingen	Rob Van Houten	Keith W. Starnes	Henk Quarles van Ufford
Daniel Solis	Arnfinn Skagestad	Eric Lenington	Kevin Brewster	Justin Keith Reeger	Prime Time Trust	John Young
Thomas J Cortese	Bekker Jens	Knut Ola Topland	Spartan Knight Investmen...	Sam Simonovich	Lee Sherman	Eran Zaidman
Dr. Paul Nathan	John Byram	Kenneth Douglas	Isaac Serussi	Ed Strasbourger	Howard Stark	Thomas Kraus
Darin Franklin	Abhishek Prasad	Pravin Shah	Lennart Pomreinke	John D'Alessandro	Ramon Ortega	Dan Rosen
Brendan Glackin	Richard Houghton	Hans Frederik Brobjerg	Xavier Chatellier	Arun Anbumani	David Dorn	Nasiri Suzan
Khuzema A. Savai	David Lanfair	Matthew Wagenfer Sr.	Chris Lam	Maricela Higgins	Wilfrid Jean-francois	Vincent Vanderbent
Brad Hallisey	Christian Verwiebe	Rob Van Houten	Matthieu Jacquier	Matthew E Dick	George James	Peter Aronsson
Nigel Anthony Reading	Tobias Foyen Foyen	Janis Kovalevskis	Clif Whittaker	Manuel Aschwanden	Ivan Arangelov	Dennis G Morgan Sr
Merk Henkel	Devin Flake	Lonnie D. Franks	John Schut	Mark Willard	Konstantinos Stamatoukos	Kenneth Edwards
Lamar Barnes	Dmitry Strizhak	Gabriel Ferrer	Luke Evans	Olof Hallstrom	Cesar Cristian Andrei	Cecilia Pacheco
Jeff Hung	Macie Serfass	Kristen G	Adam Bhakrani	Matthew Jenkins	Anil Sunny	Paul-alvin Chad Phan
Colleen Coleman Ryan	Matthew Snow	Angel Vasilev	John Milu Truesdale	Harvir Humpal	Kav Khalsa	Sulejman Sarajlija
Monica Ladron De Guevara	Melvin Caillender	Arthur Fayzullin	Mark Van Thuyne	Roderick Herron	Abdurrachman Mappuji	Neili Young
Ralf Eisenreich	Allan Terry	Gandharv Bhatara	Shellie Voisard	Olivier Wullen	John D'Alessandro	Eric Choi
Howard Wilk	Glenn Payne	Chi Zeng	Peter Gage	Bo Rasmussen	Cristovao Da CUNHA	Jeff Fuja
Gordo Gomez	Zeus Miguel	Bo Andersson	Kevin Lovell	Euclides Jose Marin	Euclides Jose Marin	Christopher A Dellario
Vijay Machado	Isaiah Immanuel Fountaine	Kallie Vanderboom Hartm...	Oswin M Browne	Chris McGowan	Ken Mora	Lap Gong Leong
Leonardo Dos Santos Cle...	Ben Smith	Angelo L. Gonzalez	Brian Gautreau	Tori Park	Rumailah Buenavente	Jim Gee
Terry Fears	Darshak M Patel	Ric Mucklow	Rob Van Houten	Roberto Carlos Miguel	Khuzema A. Savai	Christian Rishoj
Tobias Berens	Dan Rosen	Dharmendra Prasad	Manuel Aschwanden	Lauren Tarlowski	Richard Petit-Frere	Andre' DeGruchy-Bott
David Krug	Constance OBryant	Oniong Ma	Patrick Ip	Donald Huang	Brian Cooper	Scott E Kaplan
Edward Sliver	Cesar Fojas	Pino D'Oro	Peter Christensen	Chris Raber	Nick Hoath	Naina Holse
Lyie Kelley	Konstantinos Stamatoukos	Valmiki Sanyasi	Pascal Sierens	John Corrigan	Niko Portokalis	Sumanth Narra
Dr. Paul Nathan	Ian Dale Harris	Steve Grossmann	Andrew Payne	Charles Daniels	Gladkikh Artem	Matt Swayne
Vincent Vanderbent	Mark Montgomery	Heidi Hash	Stephen Massey	Douglas Walton	Colleen Coleman Ryan	Vince Smart
Martin Aavik	Mark Plotnick	Randall Huddleston	Robert E Larson	Christopher Willey	Paul Varkey	James Field
Craig Friedman	Charles A. Olson	Barbara A Ringwald	Bogdan Milin	Marco Price	Popuri Krishna	Frank Liu
Garrison Kurth	Alvin Tsui	Charlie Douglas	Eustachio Caporusso	Dean Kennedy	Chester Sappington	Meredith Hugh Trimble
Anders Norstrom	Melkamu Gezahagne Wol...	Katherine M Mayo	Stephen William WALLS	Marvin Belsky	Robert F Fitzgerald	Deji Akinymi
Christian Hovden	J R	Cameron Arndt	Michael D. McIntosh	Lawanda Marrero	Adam Strandberg	Phillip Mullinax
Patrick McHargue	Mikael Asplund	Antoine Blondel	Lia Luczynski	Kirk D Anderson	Alden Fitzsimmons	Warren L. Forman
Thomas Klauset Aurdal	David G McEwan	Christian Hovden	Taylor Caster	Samarth Beri	Ken West	Cameron J. Figgins
Richard R Haas	Cory Curtis	William Byars	Armin Azima	Marco Bartz	Jeffrey B Colton	Stephen William WALLS
Joshua Infantine	Derrik Oates	Thomas Klauset Aurdal	Patrick McHargue	James William Mitchell	Nathan Boyer	Gregory K Plambeck
Patricia Miller	William Pentler	Christopher Helfers	Antoine Blondel	Baste Larsen	Marco Bartz	PI SANTIAGO
Paule Ladne	Darly M LUELLEN	Monica Liberatore	Rodney Scott	Morris Gelman	Andy Chimicles	Albert Winnemuller
William Mendez	Gemma TRAZO	Robert Webster	Moncia Benjamin	Armando R. Venegas	Daniel Corbett	Joshua Infantine

Adimchi Onyenadum	Warren Mattix	Nemanja MILOSEVIC	Ty Claus	Bob McMahon	Michel P Cairns	Todd Hahn
Stephen William WALLS	David Muller	David M Walker	David M Helm	Kraig L Morris	Rob Bunn	Grant Wehrkamp
Antoine Blondel	John Lowe	Adam Fishback	M Ichael Sampognaro	Hye Yeon Jeon	Francis Scott LaPlante	James C Yates Jr
Peter Lugerbauer	Lachlan Ennis	Joshua Beaman	Reece Arnott	Manfred Bartz	Raman Sundararajan	David Gholami
Gloria Su	Charles Kirk	Jeffrey Mitchell	Kristina Martini	Rogier Brussee	Alexandru Balut	Peter Mattsson
Greg Wiltsey	Klaus H. Wolf	J. Zutt	Mark Sloan	Mikhail Popov	Erik Petersen	John Roehling
Karl Miossa	Bengt Gustafsson	Nathaniel Richter	Michael Melnick	Jeffrey Siebrecht	Josef Stastny	Michael Louis Helperin
Michael Sander	Jordan Boekel	Jordan Boekel	Rocky James Murray	Carmine Barone	Alfred R.Lacy	Jim Von Eiff
Richard Bjelland	Alan Jay Schoenberg	Chang Woo Lee	Edward F Nash Jr	Clayton Howard Smith	Luc Lavier	Joshua Fowler
Christophe JEANNIN	Mohamed Ali Reza	Leonora L Uy	David Tayler	Karl Weaver	Edwin Sullivan	Sander Adamson
Robert Jacques	Joseph Green	Frederick Staats	George Eastman	Ian Gary Goldwater	Benjamin Ferris	David Shen
Josh Reed	Russell Edward Robles-th...	Jonathan Stromberg	Dana N	William Banks Miller IV	Jim G Smith	John O'Renick
Robert Noack	Karen Emmanuel	Greg Pitnar	Jonathan Locke	Mack Shelton	Manjunath Devanesan	Cameron McCord
Stephane Bourgoin	Bob Cozzi	Richard Hannan	Steven Sawyer	James Van De Ven	Joe Stephens	Anthony James Alarcon
Matthew Gustafson	William Miller	Xavier Anguela	Donald V Stitz	Paul & Nancy Blanco	Robert Biegler	Joseph Preston
Joshua R Neuman	Benjamin William Millar	Michael E Reininger	Brian Widrig	Lourdes Tam	Terence Teruya	Mike Briggs
Grant Crene	Greg Bradbury	Steve Davidson	Keith Edstrom	James Dowdell	Randy Mantz	Brian Stewart
Antony Miguel	Dennis W. Brown	Michael L. Langley	John Gaczewski	John Brancato	George Gottschalk	Youngchae KIM
Phillip Pursell	Nixon Augustin	Dr. Axel Kowald	Taiwo Fakunle	Ryan Brown	Ray Fucillo	Michael Assoulina
Terrence Cowman	Wei Sid	Melvin Kestner	James Walter	Dave Morgan	Elizabeth Pasternak	Francesco Gitti
Ryan Henrichson	Luis Martinez	Lindsay McGuinness	Thomas B. Lyons	Ian Bone	Spencer Smith	Theresa K Hatfield
Jeremiah Howard	Nick Sires	Pavel Jirousek	Cynthia Thompson	Bobby Silachet	Frank Tvetter	Thomas H Ward
Sue Dudkowski	John David Arena	Jannon Frank	Jad Ghandour	Kieran Smith	Tyrone Alexander	Michael Quest
Martin Atkins	Jesus Aguilar	Linda Williams	Alyssa Suthertown	Dennis Tell	Wayne Finkelstein	Darren Graves
Cameron Smith	David West	Galen Siler	Christopher Nieldt	Sandra Freed	Long Ho	Constance L Richter
Mehlon D. Horton	Walter Pharris	Craig Glasby	Tim Pledger	Peter Siaw	David W Funk	Joakim Andreas Bengtsson
Robert Ollerton	Moonshot Fund	Liviu Vanoaica	Michael Delaney	Dennis Peterson	William Purnell	Armando Escalante
Qiang Lai	Jude Kidder	Zach Campeau	Robbin R Dawson Gst Tru...	Robert Woodward	Thomas Jones	Martin Collins
Carol Ging	David Volz	Justin Leitor	Albert Perrien II	James C Andersen	Annie Umbrecht	Peter Thomas Mohr
Dan Bishop	Megan Kane	Prioul Adrien	Erik Stafin	Kristian Knorr Jensen	Daniel Babcock	Boris Epstein
Valerie Borden	Kwok Cheung Law	Sam Webster	Brendan Byrne	Massimiliano Andreatz...	Maïja Davlouros	Gary King
Jessica Schmidt Decatrel	Connor Whitman	Jolie Jantz	Jeffrey LaGrasso	Capatoria Wilson	Glenn Patterson	Gregory Boyle
Justin Malestein	Michael J Funk	Kyle Piotrowski	Warren Upham	Allen Wong	Steve Wood	Nathan Dobbins
Neville George	Matthew Morris	Andrew Nazarechuk	Dana Swanson	Marcin Snieg	Travis Shoemaker	John David Arena
Mohamed Almheiri	Sophie Barnes	Ronald Balsys	Walter Rowntree	Michel Simixis	Francis Scott LaPlante	Michael Ratty
Dilip Ravindran	John Schraufnagel	Roman BABJAK	Gert Willems	Marcin Snieg	Dana N	Neal Allen
Jason Leeming	Christopher Nieldt	Michael Quest	Jason Bryant	Jim G Smith	Martin Lester	Eliot Solomon
Michael Louis Helperin	Kathleen Arnold	Amy S WARNER	Yogendra Kumar Patel	Roland Burrows	Bengt Gustafsson	John O'Renick
James Garcia	Joseph W Hess	Jesse Spears	Sander Adamson	Joseph C Kim	Paul Hays	Joseph Klock
Rodney Corder	Matthew Howland	Peter A SHAY	Michael Assoulina	John Lowe	Lachlan Ennis	James Morreau
Dennis W. Brown	Elicier Navarro	Andrew Nordmeier	Aske Simon Christensen	Craig Danese	Howard Talesnick	Michael Cupp
Ronald David Glassman	Adrien Hamelin	John Brooks	Raymond HARTMAN	William Miller	David Tayler	Fabian Seither
Sandeep Kadagathur Vadi...	Leo Chaloux	Gaylord Fines	Michael E Wendel JR	Scott Nesbitt	Dirk Dorony	Thomas Smith
Bobby G Corum	Devarajan S. PUTHUKARAI	Rocco Roina	Bryan VanGelder	Neville George	Josh Reed	Thomas J Abell
Ilya Scharrenbroich	Robert Durall	Chang Woo Lee	Matthew Ewer	Filipe Peeraly	Sean O'Donnell	Neil Dinh
Kevin Madsen	Rick Duffy	Niall Emmart	Alan McNea	Jon Hess	Kevin Keel	Peter Lugerbauer
Jean Brinkman	Anthony Joseph Della Sala	Mark Arruda	Jose Flores	Jason E Pendleton	Daniele Rolando	Sulexan Chery
Avinash Shukla	Davender Bhardwaj	Benjamin DWYER	Nael Altoon	Abbass Sekhavat	Deviprasad Mulluru	Chad Granofsky
Bradley Moore	Alex Fader	Rob Miller	Emmanuel Kamberov	Jeffrey Parkin	John HYDER	Stephen Ruegg
Zach Cochran	Christoph Trager	Benlini Galindo	Bryan Johnson	Mark Skinner	Jeffrey Alan Peck	William W Williams
Seth Sturm	Dennis Peterson	Kieran Wyse	Michael Gardner	Daniel Speciale	David Rica	Ty Moline
Richard Campbell	Kyle Sheepwash	Matthew Gustafson	J. Zutt	Richard Machina	Albert Perrien II	Steven Wogstaff
Rogelio Toledo	Alexander Gray Pollard	Arne Rusek	William Nemes	Nathan Blackman	Rogier Brussee	Lindsay McGuinness
Nagapradeep Sanikommu	John Luong	Dustin DuBose	Tim Gargiulo	Dylan Schweitzer	George Quarrantey	Benjamin Ferris
Marshal Hatch	Chandru Jagadeeswaraiah	Amilia Alcema	Adam Lafontaine	Justin Malestein	Daniel Liebowitz	John Roehling
Jake Annunziata	Kevin Kell	Dawn Elford	Shaun Quinn	Steve Barnett	Kevin Bowens	Uwe Dobberstein
S Kennon Brown	Jeremy Loo	Noah Koon III	Michael Bankson	Alan Tonkin	Richard Terris	Brad Soucek
Herbert Winters	Walter Rowntree	Bjoern Nykvist	Sander Dan Hoedt	Marcel Vijfwinkel	Benoit Tennadillos	Kevin Porter
Guenadi Jilevski	Patrick Enweronye	Michael Teske	Gary Cartwright	Gordon Tisher	Roberto Feng Chang	David Reardon
Richard K. McQuillin	Gregory Kenneth Van Dyk	Daniel Mouritzen	Marcin Snieg	Dennis W. Brown	Christopher A Smith	Paul Aldrete Jr
Vijayakumar Aluru	Thomas White	Sultan Shafei	Rainer Friebl	J Guy Laughlin	Scott Bourne	Jeff Baum
Michael Bryant	Carmen Johnson	Paul FREY	John David Simnett	Patrick Richardson	Justin Yeash	Robert L Mudge
Jeffrey Siebrecht	Ankur Patel	Arne Talsnes	William Colvin	Alvin Ralph Perry	Howard Kohn	Logan Zoellner
Jerry Mitchell	Paul Claybrook	Muhammed Negiat Resul	Michael Gazda	Joseph Purcella	Daniel Schmitt	Floyd Wesley Jr.
Daniel Loflin	Zack Van Prooyen	David Cornwell	Stephen R. Messman	Jason Rigby	Jonathan Bonaventura	Randal Wayne Stockwell
Andrea Shavonne Smith	James R Perkins	Zahed Hossain	Robert Lee Pike	Daniel R Severa	Ferry Tanu	John Prestidge
Mitchell S Lankford	Jeffrey A Hudson	Ronnie Hawkins	Mark Reconnu	Timothy Baxter	Rocky MOREAU	Edward Kelly Medlock
Paul Austin	Blaine Crem	Ryan Boyd	Shelby Thuruthumaili	Kent Pittman	Craig Foster	Mike Diaz
Greg Wright	Maurice Bos	Paul Curtis	Jason Ingram	Darren Tessitore	Terry Emmons	Aris Fortajada
Sead Pepic	Janet Kay Herring	Ben Barnett	Michael Louis Helperin	Remond Windley	Frodo Skywalker	Anthony Kay
Chirag Patel	Lawrence Planamento	Michael Connolly	Mohammed Ellis	Lauren McVey	Thomas BERNARD	David Ketraïis
Anthony MASARYK	Albert Perrien II	Craig Ephraim	Glenn Baptiste Siton	Jean Baptiste Siton	Alexandru Balut	Kevin Madsen
Andrew Tomlinson	Indre Larsen	Kyle Haines	Robert C. Austin	Bengt Gustafsson	Nick M	Corey Hoffman
Harlan Kawamoto	Sergio Lopez	Robert Embry	Michael Hill	Alfonso CAPRIATA	William Bradford Reynolds	Peter Crane
Ron Nelson	Florian Heinholt	Mr Keith A. Milham	Bruce Bolick	Rajendra Pandey	Henry Wyatt MOORE	Dana N
Jason Kaunas	Justin Adams	Chris Suozzo	Kyle Piotrowski	Peter A Marikis	Michael Sander	Brian Augenstein
Allen Green	Peter Emmons	Chris Grey	James Ormond	Bhavesch Chauhan	Hershel Barg	Kevin Skahan
Adriene Dumadapat	Douglas E Michel	Frantz Jones	J P	David Morgan	Jason Graham	David Krosschell
Kiki Yaw Serpong	Richard H Jones	Louella D.Moreno	Robert Evans	Edger Bonilla	Von Marsh	Vernon KINNER
Jeffrey M Carapella	Frederic Lafon	Charles Reinwald	Brian Moore	Todd Meyer	Jonathan Stout	Wesley Kotcher
Michael Muller	Lachlan Ennis	Matthew Kelsay	Mark Viegas	Amaechi George Ozor	Walter R Bartram	Stephen Barbie
Darren Graves	Muhammed Hassan	Ramsay Hoguet	Ashwani Sharma	Patrick Jenne	Francois Sarasin	Shizuka McNeill
Stanley Kuntz	Loletha Shephard	Florian Rais	Walter R Creasey Jr	Grgoire Notz	Clemens Von Schonborn...	Peter Lugerbauer
Enos Smith	Claude Sarasin	Isabel Sarasin	Eric Cantrell	Jeffrey Allen Ceglarek	Jan Wieronski	Colin Hammond
Wilhelm Maximilian Auers...	Craig Whitmore	Houston George	Thebaud Chergui AGATHE	John Jamieson	Cameron McCord	Youssef Barbour
Christopher Rondonmansi	Bharathi Nanjappa	William Tubman	Ross Hanson	Lee Gabardi	Christian Davenport	Daniel W. Loyer
Bruno Cruzate	Obed Saint-Louis	Ryan Hood	Deborah FROUNFELKER	Lawrence O Petersen Jr	Parry Nickerson	Arthur B Kennedy
Jimmy Hays	William Stahl	Ken M Green	Gary Katelansky	Ian Bone	David Corn	David Newcomer
Michele Moro	Julie JONTE	Frantisek Okal	Anael Buchegger	Tim Trischuk	Laure Mantillari	Kalle Pihelgas
Franco Manna	Stefan Roubroeks	Daniel Hayden	Daniel Shisler	Marti Ranky	David Smith	James Walker
Alain Daerendinger	Syamack Ganjavian	Sonja Palmer	Lewis Judd	Brian Murphy	Nicolas Major	Michael McCormack
Rebecca Brown	Peter Lee	Ajit Panikulam	Josiah Carlson	Enric Guenther	Cristian Temelle	Johan Smit
Thomas Prechal	William Alford	Adisa David Akinbami	Vijay Saaraswat	Amanda Goins	Michael Kattejohn	Albert Perrien II
Chris Carter	Wayne Phillips	Darlington Etumnni	Jose Valdez	Scott W Snapp	Mohammed Ellis	Tal Rachleff
Justin Stacey	Roy Johansson	Larry Tom Bendix	Frederique Berman	Srinivas Katta	Rebecca Urciuolo	Nenad Bulic
Karthikeyan Gopal	Evan DiPetrillo	Andrew Dombrowski	Von Marsh	Alexander Spillmann	John Roehling	Bharathi Nanjappa
Nicholas Vanarelli	Tiger Z Du	Andrew Collins	Cheoma Smith	Kevin Andrew Keegan Rei...	Guenter Pramstrahler	Thomas Furstenberg-Carr...
Amin Alborzian Deh Sheikh	Joshua Jonathan Burroug...	Nael Altoon	Albert Douglas Person	Rick Dodge	Charles Y	Jeff Moulton
Eng Huu	Igor Anosin	Brian Drummond	Venatius Che Nde	John Hodgie	Steve Heyward	Rick Willoughby
Jason Graham	Michael Bankson	Marcelo Santos	Bruce Weber	John Roehling	Rick Willoughby	Steve Barnett
Arne Rusek	Justin Yeash	Frederick Everett	Nasser Halwani	Guenter Pramstrahler	Steve Barnett	Steve Barnett
Jonathan Rabon	Leonard F Auman	Michael Sklar	Mark Molckovsky	Charles Y	Steve Barnett	Steve Barnett
Parth Chopra	Matthew Sheahan	Justin Wynn	James Turner	Steve Barnett	Steve Barnett	Steve Barnett
Jesse Lawrence Barrett	Joseph Francis	Michael Connolly	John Czarniecki	Steve Barnett	Steve Barnett	Steve Barnett
Jason Adams	Adam Hruby	Jan Brouwer	Hugh Vittorio Pizzi	Steve Barnett	Steve Barnett	Steve Barnett
Sachin Arakeri	James Barnett	Renu Goel	Gert Willems	Steve Barnett	Steve Barnett	Steve Barnett
Will Thorntwaite	Phillip J. Haselbauer	Marek Tihanyi	Edward Carmeliet	Steve Barnett	Steve Barnett	Steve Barnett
Craig Brown	David Martignelli	Robert Fredison	Patrick Tohara	Steve Barnett	Steve Barnett	Steve Barnett
Megan Mullin	Philip Gibson	Ross Hohepa	Josianne Dupuy	Steve Barnett	Steve Barnett	Steve Barnett

Xavier Syevens	Kamal Kishore	Cristian Dan Pirnog	Brian Schomisch	Alexander Koppisch	Eric Pfitzenmaier	Mathew J Kaczinski
Jessica CLAUDIO	David L Kraft	Kamalakar Rambhella	Anthony Taylor	Antonio Casellas-Bond	Chad N Ava Vickrey	Brandon Sutton
Andrew Neely	Todd Jackson	Steven M Robinson	Natalie Chu	Charles B Roesset	Paul Camp	Dennis Cavaille
Jeffrey Sue	Vern Babka	Gordon Slater	Jon Trevor Weeks	David Butler	Norris Reynolds	Johan Fehr
Gabriel Browne	Henry D Perry	James Benson	Paul Lee	Max Trunov	Mubarak Mustefa	Alexander Rojas
Peter Loder	Mindeugas Kojelis	Lorin Park	Paul Haye	Gerald Pirchmoser	Rob Northrop	Adam Sperling
Jackson Clark	Doug Kamin	Nikolche Mihajovski	Mark I Hunter	Mathias Weibel	Dane Jones	Erick Eaton
Gulnaar Zafar	Carl Welti	Francis Scott LaPlante	Curt Hayes	James E. Mooney	Rogier Brussee	Janica Barnett
Jeffrey E. Modesitt Jr.	Sumith Jain	Andrew Lee Rutherford	Durwin D Cobeen	Michael Griew	Charles Brinkworth	Christopher Hebert
Dennis Bradley Price	J S	Robert Pike	Jean Luc Eggen	Todd Kleinbrook	Susana Christina Claudia...	Manuel Stacey
Justin Allan Hruby	Robert Lewis	Ma Cecilia CRUZ	Randolph Boyd-Martinez	Preston Scantlebury	Martin Lukas	Benjamin DWYER
Utkarsh Gupta	Scott Grossman	Sanjeev Munjal	Russell Edward Robles-th...	Adrien Hamelin	Josh S.	William Stacey
Mohamed Jabbar	Kevin Scott Miller	Baliram Patiram	Adam Gotch	Andrzej Malachowicz	Ronen Adler	Jason Roberts
Ivar Magne Gjedrem	Melvin Kestner	Charles Gasser	Demetrio Campos	Keaton Albers	Antoine Williams	Mike Mathioudakis
Sandy Toth	Jan Tichy	Frank E Hill	Larry Ogee	Edmond Fernandez Jr	William Johnson, IV	Richard S Mackin Jr
Andrew Bowen	Dennis Peterson	Brian Thomas Kitchener	Colin Traquair	Michael Bosland	Cristian Dan Pirnog	Cristian Temelie
John Lowe	Gertrude Denk	Brian Grigsby	Gerald Pirchmoser	Ronen Adler	William Colvin	Melissa Billups
Lachlan Ennis	Enric Guenther					

## Thank You!

### From the LPPFusion Team



**Eric J. Lerner**  
President and Chief Scientist



**Ivana Karamitsos**  
Chief Information Officer,  
Communications Director  
*Ivya studied mathematics and classical music in the former Yugoslavia and received a degree in Computer Science from Binghamton University, SUNY in 2003 before joining our team in 2010.*



**Dr. Syed Hassan**  
Research Scientist  
*Dr. Hassan, a plasma physicist, has more than 20 years experience with the dense plasma focus device. Before joining LPPFusion in 2015, he worked for Purdue University's School of Nuclear Engineering.*




**Rudolph Fritsch**  
Mechanical Engineer,  
Secretary  
*Rudy has been President of Allsteel, a manufacturer of industrial metal-forming equipment, for 15 years. As an engineer and entrepreneur, he ran a successful family business in Canada for decades.*



**Dr. Warwick Dumas**  
Simulation Researcher  
*Warwick earned a Ph.D. in Applied Mathematics from the University of Leicester before joining LPP in 2012, where he simulates the plasma filaments that form when the capacitor banks are discharged.*







**Dr. Robert Terry**  
Computational Physics  
Consultant

*Dr. Terry has had over 35 years of experience in simulation of plasma phenomena, including over 20 years at the US Naval Research Laboratory developing innovative methods for modeling the Z pinch.*



**Dejan Simurdic**  
IT Administrator

*Dejan is a Software Developer/Data Analyst with over 13 years of experience. He worked in multiple industries and in over 20 different coding and database platforms. He was born in Serbia and spent 3 years in Africa before coming to the US.*

## Details

### The Board of Directors

DIRECTOR	OCCUPATION	JOINED
<a href="#">Eric J. Lerner</a>	Physicist @ LPPFusion	2003

### Officers

OFFICER	TITLE	JOINED
<a href="#">Eric J. Lerner</a>	Chief Scientist	2003
<a href="#">Rudolph Fritsch</a>	Secretary Treasurer	2015
<a href="#">Ivana Karamitsos</a>	Chief Information Officer, Communications Director	2010

### Voting Power

HOLDER	SECURITIES HELD	VOTING POWER
Eric Lerner	140,020 Class B and Class A Common	100.0%

### Past Equity Fundraises

DATE	AMOUNT	SECURITY	EXEMPTION
02/2015	\$4,439,373	Common Stock	Section 4(a)(2)
09/2015	\$354,200	Common Stock	Section 4(a)(2)
11/2015	\$1,252,250	Common Stock	Section 4(a)(2)
05/2018	\$963,250		4(a)(6)
09/2018	\$339,706	Common Stock	Regulation D, Rule 506(c)
03/2020	\$615,375		4(a)(6)
12/2020	\$591,125	Common Stock	Regulation D, Rule 506(c)
08/2021	\$672,750		4(a)(6)
09/2021	\$159,880		Section 4(a)(2)
06/2022	\$39,000	Common Stock	Regulation D, Rule 506(c)

*The use of proceeds is to fund general operations.*

### Outstanding Debts

None.

### Related Party Transactions

None.

### Capital Structure

CLASS OF SECURITY	SECURITIES (OR AMOUNT) AUTHORIZED	SECURITIES (OR AMOUNT) OUTSTANDING	VOTING RIGHTS
-------------------	---	--	------------------

	AUTHORIZED	OUTSTANDING	
Class B Common Stock	400,000	324,267	No
Class A Common Stock	20	20	Yes

SECURITIES RESERVED FOR  
ISSUANCE UPON EXERCISE OR CONVERSION

Warrants:	0
Options:	19,008

## Risks

The SEC recently approved amendments to Regulation Crowdfunding in which the fundraising limit for crowdfunding issuers will be increased from \$1.07 million during a 12-month period to \$5 million during a 12-month period. These amendments will take effect 60 days after the publication in the Federal Register. The Company reserves the right to increase the Maximum Fundraise Target once such amendments take effect. If the Company increases the Maximum Fundraising Target, investments made prior to such limit increase may be diluted accordingly.

**Dilution Risks** You should understand the potential for dilution. Each investor's stake in us, could be diluted due to our issuing additional shares. In other words, if we issue more shares, the percentage of the Company that you own will decrease, even though our value may increase. You will own a smaller piece of a larger company. This increase in the number of shares outstanding could result from a stock offering (such as an initial public offering, a crowdfunding round, a venture capital round or angel investment), employees exercising stock options, or by conversion of certain instruments (e.g., convertible notes, preferred shares or warrants) into stock. If we decide to issue more shares, you could experience value dilution, with each share being worth less than before, and control dilution, with the total percentage an investor owns being less than before. There may also be earnings dilution, with a reduction in the amount earned per share (although this typically occurs only if we offer dividends, and most development and early stage companies are unlikely to offer dividends, preferring to invest any earnings into the Company). The type of dilution that hurts early-stage investors mostly occurs when the company sells more shares in a "down round," meaning at a lower valuation than in earlier offerings. If you are making an investment expecting to own a certain percentage of the Company or expecting each share to hold a certain amount of value, it is important to realize how the value of those shares can decrease by actions taken by the Company. Dilution can make drastic changes to the value of each share, ownership percentage, voting control, and earnings per share.

However, the Shareholder's Agreement does offer you the possibility of maintaining your percentage of the company, in the event of a new offering, by buying shares on the same terms as those offered to others.

COVID-19 can materially impact our business.

It is unclear how long the COVID-19 pandemic will last and to what degree it could hurt our ability to generate revenues.

Our future success depends on the efforts of a small management team. The loss of services of the members of the management team may have an adverse effect on the company. There can be no assurance that we will be successful in attracting and retaining other personnel we require to successfully grow our business.

Rudolph Fritsch is a part-time officer. As such, it is likely that the company will not make the same progress as it would if that were not the case.

**Control by Majority Stockholder** Even if this offering is fully subscribed, Eric Lerner, who serves as an officer and our sole director, owns 100% of our Class A Voting Common Stock, and therefore maintains control. The Class B Common Stock does not have any voting rights. Therefore, investors will not have the ability to control our management. Notwithstanding the foregoing, Mr. Lerner and certain holders of our Class B Common Stock are parties to the Shareholder Agreement, pursuant to which the approval of certain holders of Class B Common Stock is required by the Company, to increase executive compensation beyond certain levels, increase the authorized number of shares, create new classes of shares, or enter into transactions with affiliates that have a value in excess of \$5,000.

**Limited Transferability and Liquidity** Each investor agrees that it will acquire our Class B Common Stock for investment purposes only and not with a view towards distribution. Certain conditions imposed by the Securities Act must be satisfied prior to any sale, transfer, conversion or other disposition of our Class B Common Stock. In addition, each investor shall sign a Shareholder Agreement (the "Shareholder Agreement"), which imposes certain additional restrictions on the transfer of the Class B Common Stock. Under the Shareholder Agreement, until such time as we become a public company, no Shares may be sold or transferred without first offering us and all of the other holders of Class B Common Stock the right to purchase such Shares. Excluded from this provision are transfers resulting from the death of a shareholder or a transfer to an affiliate of the

shareholder. No public market exists for our Class B Common Stock and no market is expected to develop.

The Company plans on expanding its business in further research stages and eventually through the introduction of commercialization and marketing campaign. Any expansion of operations the Company may undertake will entail risks. Such actions may involve specific operational activities, which may negatively impact the profitability of the Company. Consequently, shareholders must assume the risk that (i) such expansion may ultimately involve expenditures of funds beyond the resources available to the Company at that time, and (ii) management of such expanded operations may divert Management's attention and resources away from its existing operations, all of which factors may have a material adverse effect on the Company's present and prospective business activities.

If a prototype generator is achieved, commercialization will be a remaining hurdle. Significant commercial interests in existing energy sources may be able to delay such commercialization. Many other competitors may well take a large share of the market for our devices, in regions not covered by our patents, by challenging the patents, or by ignoring them.

While we believe we have a good chance of success, net power from fusion has not yet been achieved by anyone, and it's entirely possible that unexpected problems will arise. We won't know for sure until the experiments are complete. It's possible that the plasma won't behave the way we expect. There may also be engineering difficulties which delay the tests.

Even if we achieve net energy production in a laboratory device, we may not be able to overcome the engineering challenges to produce a working prototype generator. Heat removal is a significant engineering challenge and while this now appears possible within existing technology, it is near the limit of that technology. The x-ray collection device has never been built and unexpected difficulties may arise with that as well.

The Company is still in the R&D phase and has no profits to date. It has been financed primarily by investment. Losses to date have been a significant fraction of total investment, and have been over \$8 million. Such losses are expected to continue until licenses in the Company's technology are sold, which is projected to occur no sooner than 2025. Delays in the sale of such licenses could lead to continued losses.

In the early stages of development, the Company's business will be significantly dependent on the Company's management and scientific team. The Company's success will be mainly dependent upon Eric J. Lerner, and his loss could have a material adverse effect on the Company.

The Company has significant competition in the existing energy industry, and some of these competitors have significant resource bases with which to compete. In the particular field of fusion energy, other proposed fusion devices are in various phases of development, although no project has demonstrated net power generation yet. Primary competitors include General Fusion and TAE.

Our business strategy depends on the widespread adoption of our technology. We do not have an existing customer base, and do not anticipate the development of a customer base until we have proven our technology. While we believe we can develop a customer base, our inability to do so could have a material adverse effect on us. Although we believe that our products may eventually offer advantages over competitive companies and products, no assurance can be given that our products will attain a degree of market acceptance on a sustained basis or that we will generate revenues sufficient for sustained profitable operations.

**Terms of Subsequent Financings** We may need to engage in other common equity, debt, or preferred stock financing in the future. As a result of these additional offerings, your rights and the value of your investment in the Class B Common Stock could be reduced. Interest on debt securities could increase costs and negatively impact operating results. Preferred stock could be issued in series from time to time with such designations, rights, preferences, and limitations as needed to raise capital. The terms of preferred stock could be more advantageous to those investors than to the holders of Class B Common Stock. In addition, if we need to raise additional equity capital from the sale of Class B Common Stock, institutional or other investors may negotiate terms at least as, and possibly more, favorable than the terms of your investment, including, a lower purchase price.

**We Face Intense Competition** We compete with major and widely used and existing power generation facilities and devices, public utilities and alternative energy companies. Our primary competitors in the alternative energy space include General Fusion and TAE. In the specific field of fusion energy, other proposed fusion devices are in various phases of development, although no project has demonstrated net energy production yet. Most of our current and potential competitors have greater market recognition and customer bases, longer operating histories and substantially greater financial, technical, marketing, distribution, purchasing, manufacturing, personnel and other resources than we do. If we fail to compete successfully, our business would suffer



and we may lose or be unable to gain market share.

**Inadequacy of Funds** If we are able to raise the full amount we are seeking to raise in this offering, we believe that such proceeds will capitalize and sustain us sufficiently to allow for the implementation of our business plans. If, however, we are unable to raise the full amount we are seeking, or if certain assumptions made by management are incorrect, we may have inadequate funds to fully develop our business and may need to raise additional capital through equity or debt financings, which may not be available on favorable terms, or at all.

**Developing New Products and Technologies Entails Significant Risks** We are currently in the research and development stage. Delays or cost overruns in the development of our technology and failure of the product to meet our performance estimates may be caused by, among other things, unanticipated technological hurdles, difficulties in manufacturing, changes to design and regulatory hurdles. Any of these events could materially and adversely affect our operating performance and results of operations.

**If We do not Retain Key Personnel, Our Business Will Suffer** The success of our business is heavily dependent on the leadership of our key management personnel, specifically Eric J. Lerner and Ivy Karamitsos. If any of these people were to leave us, it would be difficult to replace them, and our business would be harmed. However, Lerner has a contract with our company prohibiting him from contributing fusion expertise to another company. We will also need to retain additional highly-skilled individuals if we are to effectively grow. Our future success depends on our continuing ability to identify, hire, develop, motivate and retain highly skilled personnel for all areas of our organization. Competition in our industry for qualified employees is intense, and we anticipate that certain of our competitors may directly target our employees and officers, all of whom are at-will employees and not parties to long-term employment agreements with us. Our continued ability to compete effectively depends on our ability to attract new employees and to retain and motivate our existing employees and officers.

**We May Experience Significant Delays or Other Complications** We may experience significant delays or other complications in bringing to market our systems. Any significant delays or other complications in the development, manufacture and/or launch, including, but not limited to, complications associated with launching our production or supply chain, or regulatory approvals, could materially damage our brand, business, prospects, financial condition and operating results.

**Management Discretion as to Use of Proceeds** Our success will be substantially dependent upon the discretion and judgment of our management team with respect to the application and allocation of the proceeds of this Offering. The use of proceeds described below is an estimate based on our current business plan. We, however, may find it necessary or advisable to re-allocate portions of the net proceeds reserved for one category to another, and we will have broad discretion in doing so.

**Offering Price** The price of the Shares has been arbitrarily established by us, considering such matters as the state of our business development and the general condition of the industry in which we operate. The Offering price bears little relationship to the assets, net worth, or any other objective criteria of value applicable to us.

**Risks of Borrowing** We may have to seek loans from financial institutions. Typical loan agreements might contain restrictive covenants which may impair our operating flexibility. A default under any loan agreement could result in a charging order that would have a material adverse effect on our business, results of operations or financial condition.

**Our Competitive Position Depends on Maintaining Intellectual Property Protection** Our ability to compete and to achieve and maintain profitability depends in part on our ability to protect our proprietary discoveries and technologies. We rely on a combination of patents and trade secret laws to protect our intellectual property rights. We also rely upon unpatented know-how and continuing technological innovation to develop and maintain our competitive position. Our patents might be challenged by third parties as being invalid or unenforceable, or third parties may independently develop similar or competing technology that avoids our patents. We cannot be certain that the steps we take will prevent the misappropriation and use of our intellectual property, particularly in foreign countries where the laws may not protect our proprietary rights as fully as in the United States.

**We May Face Intellectual Property Infringement Claims** If we receive notice of claims of infringement, misappropriation or misuse of other parties' proprietary rights, some of these claims could lead to litigation. We cannot assure you that we will prevail in these actions. We may also initiate claims to defend our intellectual property. Intellectual property litigation, regardless of outcome, is expensive and time-consuming, could divert management's attention from our business and have a material negative effect on our business, operating results or financial condition. If there is a successful claim of infringement against us, we may be required to pay substantial damages (including treble damages if we were to be found to have willfully infringed a third party's patent) to the party claiming infringement, develop non-infringing technology, stop selling our products or using technology that contains the allegedly infringing intellectual property

or enter into royalty or license agreements that may not be available on acceptable or commercially practical terms, if at all. Our failure to develop non-infringing technologies or license the proprietary rights on a timely basis could harm our business. Parties making infringement claims on our patents may be able to obtain an injunction that would prevent us from selling our products or using technology that contains the allegedly infringing intellectual property, which could harm our business.

**Unanticipated Obstacles to Execution of Our Business Plan** Our business plans may change significantly. Many of our potential business endeavors are capital intensive and may be subject to statutory or regulatory requirements. Management believes that our chosen activities and strategies are achievable in light of current economic and legal conditions with the skills, background, and knowledge of our principals and advisors. Management reserves the right to make significant modifications to our stated strategies depending on future events.

#### **Description of Securities for Prior Reg CF Raise**

Additional issuances of securities. Following the Investor's investment in the Company, the Company may sell interests to additional investors, which will dilute the percentage interest of the Investor in the Company. The Investor may have the opportunity to increase its investment in the Company in such a transaction. The amount of additional financing needed by the Company, if any, will depend upon the maturity and objectives of the Company. The declining of an opportunity or the inability of the Investor to make a follow-on investment may result in substantial dilution of the Investor's interest in the Company.

Issuer repurchases of securities. The Company may have authority to repurchase its securities from shareholders, which may serve to decrease any liquidity in the market for such securities, decrease the percentage interests held by other similarly situated investors to the Investor, and create pressure on the Investor to sell its securities to the Company concurrently.

A sale of the issuer or of assets of the issuer. As a minority owner of the Company, the Investor will have limited or no ability to influence a potential sale of the Company or a substantial portion of its assets. Thus, the Investor will rely upon the executive management of the Company and the Board of Directors of the Company to manage the Company so as to maximize value for shareholders. Accordingly, the success of the Investor's investment in the Company will depend in large part upon the skill and expertise of the executive management of the Company and the Board of Directors of the Company. If the Board Of Directors of the Company authorizes a sale of all or a part of the Company, or a disposition of a substantial portion of the Company's assets, there can be no guarantee that the value received by the Investor, together with the fair market estimate of the value remaining in the Company, will be equal to or exceed the value of the Investor's initial investment in the Company.

Transactions with related parties. The Investor should be aware that there will be occasions when the Company may encounter potential conflicts of interest in its operations. On any issue involving conflicts of interest, the executive management and Board of Directors of the Company will be guided by their good faith judgement as to the Company's best interests. The Company may engage in transactions with affiliates, subsidiaries or other related parties, which may be on terms which are not arm's-length, but will be in all cases consistent with the duties of the management of the Company to its shareholders. By acquiring an interest in the Company, the Investor will be deemed to have acknowledged the existence of any such actual or potential conflicts of interest and to have waived any claim with respect to any liability arising from the existence of any such conflict of interest.

#### Minority Ownership

An Investor in the Company will likely hold a minority position in the Company, and thus be limited as to its ability to control or influence the governance and operations of the Company.

The marketability and value of the Investor's interest in the Company will depend upon many factors outside the control of the Investor. The Company will be managed by its officers and be governed in accordance with the strategic direction and decision-making of its Board Of Directors, and the Investor will have no independent right to name or remove an officer or member of the Board Of Directors of the Company.

Following the Investor's investment in the Company, the Company may sell interests to additional investors, which will dilute the percentage interest of the Investor in the Company. The Investor may have the opportunity to increase its investment in the Company in such a transaction.

The amount of additional financing needed by the Company, if any, will depend upon the maturity and objectives of the Company. The declining of an opportunity or the inability of the Investor to make a follow-on investment may result in substantial dilution of the Investor's interest in the Company.



#### Exercise of Rights Held by Principal Shareholders

As holders of a majority-in-interest of voting rights in the Company, the shareholders may make decisions with which the Investor disagrees, or that negatively affect the value of the Investor's securities in the Company, and the Investor will have no recourse to change these decisions. The Investor's interests may conflict with those of other investors, and there is no guarantee that the Company will develop in a way that is optimal for or advantageous to the Investor.

For example, the shareholders may change the terms of the Articles of Incorporation for the company, change the terms of securities issued by the Company, change the management of the Company, and even force out minority holders of securities. The shareholders may make changes that affect the tax treatment of the Company in ways that are unfavorable to you but favorable to them. They may also vote to engage in new offerings and/or to register certain of the Company's securities in a way that negatively affects the value of the securities the Investor owns. Other holders of securities of the Company may also have access to more information than the Investor, leaving the Investor at a disadvantage with respect to any decisions regarding the securities he or she owns. The shareholders have the right to redeem their securities at any time. Shareholders could decide to force the Company to redeem their securities at a time that is not favorable to the Investor and is damaging to the Company. Investors' exit may affect the value of the Company and/or its viability. In cases where the rights of holders of convertible debt, SAFES, or other outstanding options or warrants are exercised, or if new awards are granted under our equity compensation plans, an Investor's interests in the Company may be diluted. This means that the pro-rata portion of the Company represented by the Investor's securities will decrease, which could also diminish the Investor's voting and/or economic rights. In addition, as discussed above, if a majority-in-interest of holders of securities with voting rights cause the Company to issue additional stock, an Investor's interest will typically also be diluted.

Based on the risks described above, the Investor could lose all or part of his or her investment in the securities in this offering, and may never see positive returns.

#### Restrictions on Transfer

The securities offered via Regulation Crowdfunding may not be transferred by any purchaser of such securities during the one year period beginning when the securities were issued, unless such securities are transferred:

- to the issuer;
- to an accredited investor<sup>②</sup>;
- as part of an offering registered with the U.S. Securities and Exchange Commission; or
- to a member of the family of the purchaser or the equivalent, to a trust controlled by the purchaser, to a trust created for the benefit of a member of the family of the purchaser or the equivalent, or in connection with the death or divorce of the purchaser or other similar circumstance.

#### **Valuation Methodology for Prior Reg CF Raise**

The offering price for the securities offered pursuant to this Form C has been determined arbitrarily by the Company, and does not necessarily bear any relationship to the Company's book value, assets, earnings or other generally accepted valuation criteria. In determining the offering price, the Company did not employ investment banking firms or other outside organizations to make an independent appraisal or evaluation. Accordingly, the offering price should not be considered to be indicative of the actual value of the securities offered hereby.

In the future, we will perform valuations of our common stock that take into account factors such as the following:

unrelated third party valuations of our common stock;  
the price at which we sell other securities, such as convertible debt or preferred Stock, in light of the rights, preferences and privileges of our those securities relative to those of our common stock;  
our results of operations, financial position and capital resources;  
current business conditions and projections;  
the lack of marketability of our common stock;  
the hiring of key personnel and the experience of our management;  
the introduction of new products;  
the risk inherent in the development and expansion of our products;  
our stage of development and material risks related to our business;  
the likelihood of achieving a liquidity event, such as an initial public offering or a sale of our company given the prevailing market conditions and the nature and history of our business;  
industry trends and competitive environment;  
trends in consumer spending, including consumer confidence;  
overall economic indicators, including gross domestic product, employment, inflation

and interest rates; and  
the general economic outlook.

We will analyze factors such as those described above using a combination of financial and market-based methodologies to determine our business enterprise value. For example, we may use methodologies that assume that businesses operating in the same industry will share similar characteristics and that the Company's value will correlate to those characteristics, and/or methodologies that compare transactions in similar securities issued by us that were conducted in the market.

### **Company**

LAWRENCEVILLE PLASMA PHYSICS, INC.

- New Jersey Corporation
- Organized May 2003
- 3 employees

128 Lincoln Boulevard

Middlesex NJ 08846

<https://lppfusion.com>

### **Business Description**

Refer to the [LPPFusion](#) profile.

### **EDGAR Filing**

The Securities and Exchange Commission hosts the [official version of this annual report](#) on their EDGAR web site. It looks like it was built in 1989.

### **Compliance with Prior Annual Reports**

LPPFusion has previously not complied with the reporting requirements under Rule 202 of Regulation Crowdfunding.

Late filing.

### **All prior investor updates**

You can refer to the company's [updates page](#) to view all updates to date. Updates are for investors only and will require you to log in to the Wefunder account used to make the investment.